# Dose-seeking Study of Pembrolizumab Plus Vemurafenib and Cobimetinib Advanced Melanoma

> **NCT02818023** · PHASE1 · TERMINATED · sponsor: **Yana Najjar** · enrollment: 9 (actual)

## Conditions studied

- Melanoma

## Interventions

- **DRUG:** Pembrolizumab
- **DRUG:** Vemurafenib
- **DRUG:** Cobimetinib

## Key facts

- **NCT ID:** NCT02818023
- **Lead sponsor:** Yana Najjar
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2016-07-13
- **Primary completion:** 2019-06-10
- **Final completion:** 2021-04-23
- **Target enrollment:** 9 (ACTUAL)
- **Why stopped:** Accrual to trial stopped due to high toxicity even at lowest dose of combination treatment. Patients on trial tolerating treatment at time of accrual closure still continued to receive treatment.
- **Last updated:** 2022-01-03

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02818023

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02818023, "Dose-seeking Study of Pembrolizumab Plus Vemurafenib and Cobimetinib Advanced Melanoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02818023. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*